






## AUTHOR CORRECTION OPEN



# Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer


Alessandra Fabi , Luisa Carbognin, Andrea Botticelli, Ida Paris , Paola Fuso, Maria Cristina Savastano, Nicla La Verde , Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano , Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone , Giampaolo Tortora, Diana Giannarelli and Giovanni Scambia

*npj Breast Cancer* (2024)10:13; <https://doi.org/10.1038/s41523-024-00619-5>

Correction to: *npj Breast Cancer* <https://doi.org/10.1038/s41523-023-00579-2>, published online 08 September 2023

In this article the author name Paola Fuso was incorrectly written as Paolo Fuso. The original article has been corrected.

appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give

© The Author(s) 2024